8-K

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934

Date of Report (Date of earliest event reported): April 26, 2018

NEMAURA MEDICAL, INC.

(Exact name of registrant as specified in charter)

Nevada

(State or other jurisdiction of incorporation)

001-38355	46-5027260
(Commission File Number)	(IRS Employer Identification No.)
Advanced Technology Innovation Centre, Loughborough University Science and Enterprise Parks, 5 Oakwood Drive, Loughborough, Leicestershire LE11 3QF United Kingdom	N/A
(Address of principal executive offices)	(Zip Code)
Registrant's telephone number, including area code:	00 44 1509 222912
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

[_]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[_]  Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

[_]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[_]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01.  Other Events

A corporate presentation with additional information about Nemaura Medical, Inc. (the "Registrant"), is attached as Exhibit 99.1 to this report and is incorporated herein by reference. The Registrant undertakes no obligation to update this information, including any forward-looking statements, to reflect subsequently occurring events or circumstances.

Item 9.01.  Financial Statement and Exhibits.

(d)  Exhibits.

Exhibit No.	Description
99.1	Corporate Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Nemaura Medical, Inc.
Dated:  April 26, 2018	By:	/s/ Dewan F. H. Chowdhury
		Name: Dewan F. H. Chowdhury
		Title:  Chief Executive Officer

EX-99.1

Exhibit 99.1

This presentation includes forward-looking statements that are subject to many risks and uncertainties. These forward-looking statements, such as statements about Nemaura’s short-term and long-term growth strategies, can sometimes be identified by use of terms such as “intend,” “expect,” “plan,” “estimate,” “future,” “strive,” and similar words. These statements involve many risks and uncertainties that may cause actual results to differ from what may be expressed or implied in these statements. These risks are discussed in Nemaura’s filings with the Securities and Exchange Commission (the “Commission”), including the risks identified under the section captioned “Risk Factors” in Nemaura’s Quarterly Report on Form 10-Q filed with the Commission on February 09, 2018 and in Nemaura’s Registration Statement on Form S-3 filed with the Commission on March 18, 2016. Nemaura disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

 

•Differentiated product platform; potentially disruptive product to traditional blood glucose monitoring technology Technology evolved out of Company’s fundamental expertise in transdermal drug delivery •Non-invasive, flexible and affordable adhesive skin-patch based proprietary platform technology •Skin-patch integrated with a Bluetooth-enabled transmitter that syncs to our app on users’ smart devices for continuous monitoring   •Significant advantages over traditional monitoring technologies  

•Non-invasive (Needle-free and Pain-free1) •Flexible (Daily disposable) •Affordable (Anticipated daily retail price <$2.50)   •Lead indication: Glucose Monitoring  •1 in 11 adults worldwide has diabetes (WHO) with numbers expected to grow ~50% by 2030

•The glucose monitoring market is largely underpenetrated in both the U.S. and E.U., leaving us greenfield opportunity  •Platform technology enables application / indication expansion  •Capable of reading many analytes or prescription medications present in interstitial fluid

 

Full color, high-resolution images of the data, rapidly converted using an algorithm, and displayed in various formats including tabular and graphical, with user-defined alarms for high and low readings. SugarBEAT applied to the skin, containing (i) reusable Bluetooth-enabled transmitter,  (ii) rechargeable battery and (iii) disposable skin patch.

Combined approximate size 4cm x 3cm x 9mm

 

Our proprietary BEAT™ technology platform consists of an adhesive daily-disposable skin patch integrated into a reusable Bluetooth-enabled transmitter that collects and quantifies a wide range of analytes present within interstitial fluid. The BEAT™patch extracts glucose from below the skin to an adhesive skin-patch  integrated into a transmitter The Bluetooth-enabled transmitter measures and transmits glucose data to a proprietary application pre-downloaded on user’s smartwatch / smartphone A proprietary algorithm within the application converts this data to a concentration value This value is displayed on the smartwatch /smartphone and can be forwarded on to cloud based health care team

 

vSugarBEAT® commercial launch expected Q4 2018 in UK vCE Mark granted Q1 2016 on predecessor version (watch format) vCE approval required for wireless version as adjunct device, with European Clinical Trials completed in Q4 2017 and PMA clinical trial targeted to commence in Q4 2018

<1% within 5 years Type 1 Insulin Dependent (~6.5% of diabetics) 1 Most Type 1s on Continuous Glucose Monitoring (CGM) would prefer daily continuous monitoring, therefore Dexcom and Abbott are better choices as finger prick calibration is not required for Dexcom or Libre. 3  Most Type 2s do not use CGMs and are more likely to undertake intermittent monitoring, therefore sugarBEAT is attractive due to its one-day wear flexibility, non-invasiveness and lower cost.2  Most Type 2 non-insulin dependents would benefit from understanding factors that affect their blood sugar trends and should find that sugarBEAT’s one-day wear flexibility, non-invasiveness and lower cost make it an attractive option compared to other CGMs.